Carregant...
The Long Road to the First FDA Approved Gene Therapy: Chimeric Antigen Receptor T Cells Targeting CD19
Thirty years after initial publications of the concept of a chimeric antigen receptor (CAR), the U.S. Food and Drug Administration (FDA) approved the first anti-CD19 CAR T cell therapy. Unlike other immunotherapies such as immune checkpoint inhibitors and bispecific antibodies, CAR T cells are uniqu...
Guardat en:
| Publicat a: | Cytotherapy |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7036015/ https://ncbi.nlm.nih.gov/pubmed/32014447 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcyt.2019.12.004 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|